Sponsored Links
| New Four Year Stelara(R) (Ustekinumab) Data Show Consistent Safety Profile Over Time In Patients With Moderate-To-Severe Plaque Psoriasis |
 |
 |
 |
| Medical News - Eczema and Psoriasis | |||
|
New findings presented today from pooled analyses of the ongoing STELARA® (ustekinumab) psoriasis clinical development program showed that the safety profile of ustekinumab and rates of adverse events remained consistent and stable over time in adults with moderate-to-severe plaque psoriasis receiving up to four years of treatment... Read more: Eczema / Psoriasis News From Medical News Today
|